Details

Autor(en) / Beteiligte

• MCARTHUR, Heather L
• RUGO, Hope
• QIN ZHOU
• STEINGART, Richard
• CHAU DANG
• MORROW, Monica
• CORDEIRO, Peter
• FORNIER, Monica
• PARK, John
• SEIDMAN, Andrew
• LAKE, Diana
• GILEWSKI, Theresa
• NULSEN, Benjamin
• THEODOULOU, Maria
• MODI, Shanu
• D'ANDREA, Gabriella
• SKLARIN, Nancy
• ROBSON, Mark
• HAWKS, Laura
• GROTHUSEN, Jill
• MELISKO, Michelle
• MOASSER, Mark
• PAULSON, Matthew
• TRAINA, Tiffany
• PATIL, Sujata

Titel

A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin―Cyclophosphamide (AC) Followed by Nanoparticle Albumin―Bound Paclitaxel in Early-Stage Breast Cancer

Ist Teil von

• Clinical cancer research, 2011-05, Vol.17 (10), p.3398-3407

Ort / Verlag

Philadelphia, PA: American Association for Cancer Research

Erscheinungsjahr

2011

Quelle

MEDLINE

Beschreibungen/Notizen

• Bevacizumab confers benefits in metastatic breast cancer but may be more effective as adjuvant therapy. We evaluated the cardiac safety of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (ddAC) → nanoparticle albumin-bound (nab)-paclitaxel in human epidermal growth factor receptor 2 normal early-stage breast cancer. Eighty patients with normal left ventricular ejection fraction (LVEF) were enrolled. Bevacizumab was administered for 1 year, concurrently with ddAC → nab-paclitaxel then as a single agent. LVEF was evaluated at months 0, 2, 6, 9, and 18. This regimen was considered safe if fewer than three cardiac events or fewer than two deaths from left ventricular dysfunction occurred. Correlative studies of cardiac troponin (cTn) and plasma renin activity (PRA) were conducted. The median age was 48 years (range, 27-75 years), and baseline LVEF was 68% (53%-82%). After 39 months' median follow-up (5-45 months): median LVEF was 68% (53%-80%) at 2 months (n = 78), 64% (51%-77%) at 6 months (n = 66), 63% (48%-77%) at 9 months (n = 61), and 66% (42%-76%) at 18 months (n = 54). One patient developed symptomatic LV dysfunction at month 15. Common toxicities necessitating treatment discontinuation were hypertension (HTN, 4%), wound-healing complications (4%), and asymptomatic LVEF declines (4%). Neither cTn nor PRA predicted congestive heart failure (CHF) or HTN, respectively. Bevacizumab with ddAC → nab-paclitaxel had a low rate of cardiac events; cTn and PRA levels are not predictive of CHF or HTN, respectively. The efficacy of bevacizumab as adjuvant treatment will be established in several ongoing phase III trials.